0001797199-20-000003.txt : 20201110 0001797199-20-000003.hdr.sgml : 20201110 20201110200719 ACCESSION NUMBER: 0001797199-20-000003 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201106 FILED AS OF DATE: 20201110 DATE AS OF CHANGE: 20201110 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: GORENSTEIN MICHAEL RYAN CENTRAL INDEX KEY: 0001797199 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38403 FILM NUMBER: 201302668 MAIL ADDRESS: STREET 1: 111 PETER STREET, SUITE 300 CITY: TORONTO STATE: A6 ZIP: M5V 2G9 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cronos Group Inc. CENTRAL INDEX KEY: 0001656472 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 000000000 STATE OF INCORPORATION: A6 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 111 PETER STREET STREET 2: SUITE 300 CITY: TORONTO STATE: A6 ZIP: M5V 2G9 BUSINESS PHONE: (416) 504-0004 MAIL ADDRESS: STREET 1: 111 PETER STREET STREET 2: SUITE 300 CITY: TORONTO STATE: A6 ZIP: M5V 2G9 FORMER COMPANY: FORMER CONFORMED NAME: PharmaCan Capital Corp. DATE OF NAME CHANGE: 20151021 4 1 wf-form4_160505682132696.xml FORM 4 X0306 4 2020-11-06 0 0001656472 Cronos Group Inc. CRON 0001797199 GORENSTEIN MICHAEL RYAN 111 PETER STREET, SUITE 300 TORONTO A6 M5V 2G9 ONTARIO, CANADA 1 1 0 0 Executive Chairman COMMON SHARES 2020-11-06 4 S 0 1181499 7.1621 D 725298 D COMMON SHARES 2020-11-06 4 S 0 107851 7.9177 D 617447 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.70 to $7.69, inclusive. The reporting person undertakes to provide to Cronos Group Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (3) to this Form 4. The total number of shares beneficially owned was misreported on the reporting person's Form 3 filed on December 31, 2019, which overreported the amount of beneficially owned shares by 100 shares. The number stated in this filing reflects the correction of the misreported amount. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.695 to $8.095, inclusive. /s/ Eileen Uy, as attorney-in-fact for Michael R. Gorenstein 2020-11-10